MarginsXMarginsX
Home › Markets › Health Care › XERS

Xeris Biopharma Holdings Inc. (XERS)

XERS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$16.70
+0.24% on the day
Market cap
$3.1B
Mid cap
Revenue · 2025
$291.8M
+43.7% on 2024
Net income · 2025
$554K
0.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/0001867096-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXERS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001867096
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$291.8M
Net income$554K
Operating income$24.9M
Net margin0.2%
Operating margin8.5%
Revenue growth+43.7%
Cash$111.0M
Total assets$383.5M
P/E (computed)5507.4×
P/S (computed)10.5×

Warning signs

Cash runway
Cash-flow positive
$131.1M cash at September 30, 2026
Share count, 1 year
+10.1%
2025-10-31 to 2026-10-31 · +32.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$5.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$131.1M cash; operating cash flow $18.4M a quarter.Report 2026-09-30
Shares outstanding182,700,038 (2026-10-31); 165,924,289 a year earlier; 138,124,595 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Grand Rapids, Michigan, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $5.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$107.2M$11.3M$35.5M$131.1M$189.7M$368.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$92.1M-$31.1M$8.3M$121.7M$252.6M$335.4M10-Q 2026-08-06
Q1 2026
2026-03-31
$83.1M$2.2M$9.9M$111.8M$221.2M$314.9M10-Q 2026-05-07
Q4 2025
2025-12-31
$85.8M$11.1M$20.0M$111.0M$220.3M$291.8M10-K 2026-03-02
Q3 2025
2025-09-30
$74.4M$621K$18.4M$91.6M$219.5M$266.1M10-Q 2026-11-05
Q2 2025
2025-06-30
$71.5M-$1.9M$182K$59.3M$218.6M$246.0M10-Q 2026-08-06
Q1 2025
2025-03-31
$60.1M-$9.2M-$10.0M$58.4M$229.8M$222.6M10-Q 2026-05-07
Q4 2024
2024-12-31
$60.1M-$5.1M$2.0M$71.6M$232.1M$203.1M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-03-06
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 346 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.6%
1 month+63.3%
3 months+100.0%
Year to date+112.2%
1 year+129.5%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TLXTelix Pharmaceuticals Limited$8.92-3.36%$3.0B
LEGNLegend Biotech Corporation$15.99-8.63%$3.1B
DYNDyne Therapeutics Inc.$16.70-2.68%$3.1B
BHCBausch Health Companies Inc.$8.42+0.84%$3.2B
IDYAIDEAYA Biosciences Inc.$30.36-4.62%$2.9B
ACADACADIA Pharmaceuticals Inc.$18.67-0.43%$3.2B
VCREVicore Pharma Holding AB$10.16-1.93%$2.9B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier